Trade Mark Journal No.2026/004 23 January 2026
WO0000001894506 (5,10)
Office of origin: European Union Intellectual Property Office (EUIPO)
Date of International Registration:30 October 2025
Date of designation in the UK:
30 October 2025
The mark contains the colours purple and yellow.
International priority date claimed: 6 May 2025
(European Union Intellectual Property Office (EUIPO))
(019182904)
- Class 5
- Pharmaceutical and biopharmaceutical products and preparations for the medical treatment of gastrointestinal diseases and disorders emanating from microbiota dysfunction; pharmaceutical and biopharmaceutical products and preparations used for the treatment of cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases; pharmaceuticals used to maintain health or restore health to a human subject in the field of treatment of a disturbed microbial community, namely, for the treatment of dysbiosis, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases; biological preparations in the nature of microorganisms used to maintain health or restore health to a human subject in the field of treatment of a disturbed microbial community, namely, for the treatment of dysbiosis, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases.
- Class 10
- Medical and surgical apparatus and instruments; drug delivery devices, including medical apparatus and instruments for administration of pharmaceutical and biopharmaceutical products and preparations; drug delivery devices to treat gut microbiome-related disorders, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases; drug delivery devices to treat gut microbiome-related disorders, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, in the nature of a kit comprising a prefilled suspension bag and administration tube set.
MAAT PHARMA
Representative: ICOSA, 83 Avenue Denfert-Rochereau, F-75014 PARIS, FRANCE